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Summary
Background: The development of accurate, non-invasive markers to diagnose and 
stage non-alcoholic fatty liver disease (NAFLD) is critical to reduce the need for an 
invasive liver biopsy and to identify patients who are at the highest risk of hepatic and 
cardio-metabolic complications. Disruption of steroid hormone metabolic pathways 
has been described in patients with NAFLD.
Aim(s): To assess the hypothesis that assessment of the urinary steroid metabolome 
may provide a novel, non-invasive biomarker strategy to stage NAFLD.
Methods: We analysed the urinary steroid metabolome in 275 subjects (121 with 
biopsy-proven NAFLD, 48 with alcohol-related cirrhosis and 106 controls), using gas 
chromatography-mass spectrometry (GC-MS) coupled with machine learning-based 
Generalised Matrix Learning Vector Quantisation (GMLVQ) analysis.
Results: Generalised Matrix Learning Vector Quantisation analysis achieved excellent 
separation of early (F0-F2) from advanced (F3-F4) fibrosis (AUC receiver operating 
characteristics [ROC]: 0.92 [0.91-0.94]). Furthermore, there was near perfect separa-
tion of controls from patients with advanced fibrotic NAFLD (AUC ROC = 0.99 [0.98-
0.99]) and from those with NAFLD cirrhosis (AUC ROC = 1.0 [1.0-1.0]). This approach 
was also able to distinguish patients with NAFLD cirrhosis from those with alcohol-
related cirrhosis (AUC ROC = 0.83 [0.81-0.85]).
Conclusions: Unbiased GMLVQ analysis of the urinary steroid metabolome offers ex-
cellent potential as a non-invasive biomarker approach to stage NAFLD fibrosis as 
well as to screen for NAFLD. A highly sensitive and specific urinary biomarker is likely 
to have clinical utility both in secondary care and in the broader general population 
within primary care and could significantly decrease the need for liver biopsy.
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1  | INTRODUC TION
Ectopic fat deposition in the liver, known as non-alcoholic fatty 
liver disease (NAFLD), affects up to 30% of the worldwide popu-
lation, up to 70% of patients with type 2 diabetes mellitus (T2D) 
and more than 90% of patients undergoing weight loss surgery.1 By 
2025, it is estimated that NAFLD will be the leading cause of liver 
failure and leading indication for liver transplantation worldwide.2,3 
Despite the impact upon the liver, most morbidity and mortality in 
patients with NAFLD is driven through adverse cardiovascular out-
comes.4 There is now clear evidence that morbidity and mortality 
(both cardiovascular and liver) increase with progressive disease 
that is driven by the degree of inflammation and fibrosis as well as 
development of T2D and continued weight gain.4,5
Non-alcoholic fatty liver disease is often asymptomatic until its 
late stages when either hepatic decompensation or cardiovascular 
complications may become apparent. Accurate and early staging is 
therefore important to determine the risk of complications and to 
guide the most appropriate management strategy. The current ref-
erence standard for staging liver fibrosis in patients with NAFLD 
remains liver biopsy, which is invasive, associated with morbidity, 
resource intensive and samples only a very small fraction of the liver 
and thus may be prone to sampling error.
Routine interpretation of liver biochemistry is unhelpful in stag-
ing NAFLD; 50% of patients with advanced fibrosis or cirrhosis have 
entirely normal liver chemistry.6 Faced with this challenge, several 
non-invasive tools, including serological, clinical and imaging-based 
markers and algorithms, have been developed attempting to reduce 
the need for liver biopsy to stage NAFLD.7 However, to date, none 
of these approaches have been shown to be sufficiently robust to re-
place liver biopsy. Most have good negative predictive value, although 
their sensitivity and positive predictive value are relatively poor.
Steroid hormones are primarily synthesised in the adrenal glands 
and gonads, however, the majority of their metabolism (primarily to 
inactive metabolites) occurs within the liver with subsequent excre-
tion in the urine. Based on the paradigm of glucocorticoid excess 
(Cushing's syndrome) in which patients develop a florid metabolic 
phenotype characterised by obesity, insulin resistance, T2D and 
NAFLD,8 specific steroid metabolic pathways have been shown to 
be dysregulated in patients with NAFLD. These include the activi-
ties of the enzymes 11β-hydroxysteroid dehydrogenase type 1 (11β-
HSD1), which regenerates cortisol (F) from inactive cortisone (E), 
and the A-ring reductases (5α- and 5β-reductase, 5αR/5βR), which 
inactivate cortisol to tetrahydrocortisol metabolites (5αTHF and 
THF).9,10 However, these studies have been small and did not ex-
amine their relationship with histological disease stage. In addition, 
the complexities of hepatic steroid hormone metabolism means that 
specific ratios are influenced by the activities of multiple enzymes 
rendering their interpretation challenging.
We therefore proposed to test the hypothesis that the urinary ste-
roid metabolome provides an accurate and dynamic reflection of steroid 
hormone metabolism within the liver, and that this in turn will be influ-
enced by NAFLD disease stage. Through the adoption of interpretable 
machine learning algorithms, which simultaneously permitted specific 
pathway interrogation as well as a global analysis, we aimed to investi-
gate whether the urinary steroid metabolome offered the potential to 
accurately and non-invasively diagnose and stage NAFLD.
2  | PATIENTS AND METHODS
Clinical data and urine samples were collected from 275 subjects; 
169 patients with established liver disease (NAFLD n = 121; alcohol 
n = 48) and 106 controls without known liver disease. All samples 
were collected with full informed consent and national research 
ethical committee approval (refs. 09/H0403/1, 12/WM/0288, 07/
H1211/168, 09/H604/20, and 10/H0402/23). All patients with 
NAFLD had liver biopsy staging performed, except in six patients 
where a diagnosis of cirrhosis was made using established clinical 
criteria (clinical examination, platelets and liver function blood tests, 
liver imaging and hepatic elastography). Determination of control 
status was established by review of medical history and the absence 
of risk factors for any known liver disease. Control subjects with 
abnormal liver chemistry or with elevated tests for liver disease 
severity (see below) were excluded from the analysis. Scores for 
non-invasive markers of liver fibrosis were defined and calculated 
as follows:
• AST-to-Platelet Ratio Index = AST (IU/L)/(upper limit of normal)/
platelet count (×109/L) × 100
• Fibrosis-4 score (FIB-4) = age × AST (IU/L)/platelet count 
(×109/L) × √ALT (IU/L)
• AST/ALT ratio = AST (IU/L)/ALT (IU/L)
• NAFLD fibrosis score = −1.675 + 0.037 × age (y) + 0.094 × body 
mass index (BMI) (kg/m2) + 1.13 × Impaired fasting glucose or T2D 
(yes = 1, no = 0) + 0.99 × AST/ALT ratio − 0.013 × platelet count 
(×109/L) − 0.66 × albumin (g/dL)
• BARD score = sum (BMI >28 kg/m2 = 1, AST/ALT ratio >0.8 = 2, 
T2D = 1)
2.1 | Histological liver staging of NAFLD
Liver biopsies were performed as part of clinical care in patients with 
NAFLD. NAFLD Activity Score (NAS) (including the individual compo-
nents of lobular, inflammation, steatosis, hepatocyte ballooning and 
fibrosis) as well as NAFLD fibrosis stage (F0-F4) were assessed by 
the Kleiner staging system.11 F0 represents the absence of fibrosis, 
F1 portal or peri-sinusoidal fibrosis, F2 portal/peri-portal and peri-
sinusoidal fibrosis, F3 septal or bridging fibrosis and F4 cirrhosis.
2.2 | Urinary steroid metabolite analysis
Spot urine samples from a single void of urine were collected from 
each subject and stored at −80°C. Measurement of urinary steroid 
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metabolites was undertaken using gas chromatography/mass spec-
trometry (GC/MS) as described previously.12
In brief, free and conjugated steroids were extracted from 1mL of 
urine via a 5-step extraction method. Solid-phase extraction of free 
and conjugated steroids was performed. Steroid conjugates under-
went enzymatic hydrolysis followed by solid-phase re-extraction of 
steroids, chemical derivatisation to form ethers and finally liquid-liq-
uid extraction. GC/MS was undertaken on an Agilent 5973 MSD 
single-quadrupole gas chromatography mass spectrometer (Agilent) 
instrument allowing quantification of up to 32 steroid metabolites, 
with representation of major steroids and their metabolites from all 
the adrenal-derived steroid hormone classes (androgens, glucocorti-
coids and mineralocorticoids [Table S1]). Steroids were identified in 
SIM (single ion monitoring) mode and quantified relative to authentic 
reference standards. Multi-steroid profiling includes the metabolites 
of all precursors and end products of the major steroid hormone 
classes (androgens, glucocorticoids and mineralocorticoids; Table S1.
For each urine sample, a creatinine correction was made (see 
below) in an attempt to adjust for differing times and durations of col-
lection (urinary creatinine is excreted at a relatively constant rate and is 
widely used as a corrective factor). Data were expressed as μg steroid/g 
urinary creatinine. A separate analysis of uncorrected data expressed 
as μg steroid/1000 mL urine is presented in the supplementary data.
Measurement of individual steroid hormone concentrations and 
their metabolites permitted assessment of individual steroid meta-
bolic pathways based on the analysis of ‘precursor to product metab-
olite’ ratios. All individual steroid data were log transformed (Log10) 
prior to analysis. Product-to-substrate metabolite ratios investigating 
specific pathways of glucocorticoid metabolism were calculated as 
follows:
• 11β-HSD1 activity = (THF + 5αTHF)/THE
• A-ring reductase activity = 5αTHF/THF
In addition, we calculated total glucocorticoid excretion as 
the sum of the following steroid metabolites: Total Cortisol (F) 
Metabolites = 6β-hydroxy-cortisol + tetrahydrocortisol (THF) + 
5α-tetrahydrocortisol (5αTHF) + α-cortol + β-cortol + 11β-hy-
droxyetiocholanolone + cortisone (E) + tetrahydrocortisone 
(THE) + α-cortolone + β-cortolone + 11-oxoetiocholanolone.
2.3 | Urinary creatinine assay
Urinary creatinine measurement was performed using the 
QuantiChromTM Creatinine Assay Kit (DICT-500, Universal 
Biologicals). Five microlitre of either standard (50 mg/dL) or urine 
was mixed with 200 μL of working reagent in a 96-well plate. Optical 
density was read at 0 minute and 5 minutes at an absorbance of 
490 nm on a VersaMax Plate Reader (Molecular Devices) and the cre-
atinine concentration (mg/dL) was calculated for each urine sample in 
duplicate as per the manufacturer guidance. A mean creatinine value 
(mg/dL) was calculated from a minimum of two independent assays.
2.4 | Generalised Matrix learning vector 
quantisation computational analysis
Learning Vector Quantisation (LVQ) is a machine learning technique 
that extracts typical class representatives or prototypes from training 
data.13 For our application this translated to one typical steroid profile 
per disease stage. These prototypes can be used to classify a steroid 
profile with unknown disease stage: the most probable disease stage is 
determined by selecting the class of the prototype that is most similar 
to the new profile. The dis-similarity of a given steroid profile and a pro-
totype is defined by a distance measure, for example, the conventional 
Euclidean distance. In Generalised Matrix Learning Vector Quantisation 
(GMLVQ),14 however, the distance metric itself is adaptive and opti-
mised together with the prototypes in the same data-driven training 
process. This metric is defined through a matrix of adaptive parameters, 
termed the relevance matrix. Its diagonal elements quantify the impor-
tance of individual steroids in the classification scheme. Details of the 
GMLVQ analysis are presented in detail in the supplementary appendix, 
including the use of receiver operating charcteristic curves 15.
2.5 | Statistical analysis
Steroid metabolite ratio data are graphically represented as mean 
and standard error of the mean using GraphPad Prism version 7.02 
(GraphPad Software). Individual steroid data and steroid ratios were 
compared among control, early fibrosis (F0-F2) and advanced fibro-
sis (F3-F4) groups using the Kruskal-Wallis nonparametric test and 
pair-wise multiple comparisons between groups were undertaken 
using Dunn's post hoc test. Significance was determined as P < 0.05.
3  | RESULTS
A total of 275 individuals were recruited into the study (106 controls, 
121 with NAFLD and 48 with alcohol-related cirrhosis). Demographic 
details as well as biochemical and histological assessment are pre-
sented in Table 1 and Table S3. There was no significant difference in 
gender ratios between groups, although age was significantly different 
between all three groups. Those with advanced fibrosis were older 
than the other two groups, although controls were older than those 
with early fibrosis (F0-F2). All groups had a mean BMI in the obese 
range (BMI >30 kg/m2); BMI was highest in those with early fibrosis.
3.1 | Increased 11β-hydroxysteroid dehydrogenase 
type 1 and 5α-reductase activity in patients with 
NAFLD and advanced fibrosis
Data for specific steroid metabolites and ratios indicative of spe-
cific enzyme activity are presented in Table S2. In our cohort, 11β-
HSD1 activity, as reflected by the (THF + 5αTHF)/THE ratio, was 
increased, consistent with enhanced cortisol regeneration from 
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inactive cortisone, in patients with NAFLD and advanced fibrosis 
(F3-4) (Figure 1A), although not in those with early fibrosis (F0-
2). In parallel, we observed an increase in systemic 5α-reductase 
activity, which enhances cortisol clearance (Figure 1B). There 
was no change in total glucocorticoid metabolite production 
(Figure 1C).
3.2 | GMLVQ analysis of the urinary steroid 
metabolome can distinguish early from 
advanced fibrosis
Analysis of data using individual steroid metabolites and ratios dem-
onstrated significant overlap across all fibrosis groups and there-
fore there was limited potential to be able to correctly determine 
NAFLD disease stage. We therefore adopted a global approach using 
GMLVQ to analyse all 32 urinary steroids and metabolites (Figure 
S1A) based on the generation of prototype steroid profiles (Figure 
S1B) and a relevance matrix which indicates the importance of indi-
vidual steroids to the GMLVQ classifier (Figure S1C).
Generalised Matrix Learning Vector Quantisation performance 
was further enhanced by the inclusion of both age and BMI into the 
model (GMLVQ*) (Table 2). To address the binary problem of iden-
tifying those individuals with established NAFLD who have either 
early (F0-2) vs advanced (F3-4) fibrosis, 2D representative plots 
were produced as shown in Figure 2A demonstrating good sepa-
ration. Corresponding area under the curve (AUC) analysis of the 
receiver operating characteristics (ROC) curves suggested that uri-
nary steroid GMLVQ and GMLVQ* analysis performed as well as the 
established non-invasive serum marker algorithm, Fib-4 (Figure 2B) 
(Table 2).
Patients with liver cirrhosis are at a higher risk of developing he-
patocellular carcinoma and hepatic decompensation and therefore 
require active monitoring and surveillance. GMLVQ and GMLVQ* 
were able to accurately identify those patients with NAFLD cirrhosis 
(F0-3 vs F4) and out-performed non-invasive serological assessments 
including NAFLD fibrosis score and Fib-4 (Figure 2C,D, Table 2).
3.3 | GMLVQ analysis of the urinary steroid 
metabolome has excellent potential to 
identify patients with advanced NAFLD in the 
general population
Both GMLVQ and GMLVQ* demonstrated excellent separation and 
diagnostic ability in identifying patients with advanced NAFLD when 
compared with controls (Figure 3A,B). When used to identify those 
patients with NASH cirrhosis, there was perfect separation and AUC 
ROC = 1.0 (Figure 3C,D) (Table 2).
To determine if GMLVQ* of urinary steroid metabolite data could 
identify the underlying aetiology of cirrhosis, a further analysis com-
paring samples from patients with NAFLD cirrhosis to those from 
patients with alcohol-related cirrhosis was performed (Table S3). 
GMLVQ* demonstrated good separation and diagnostic ability to 
differentiate the underlying aetiology of cirrhosis (AUC ROC = 0.83 
[0.81-0.85, 95% confidence intervals], Figure S2).
Additional analyses were also performed separating data by gen-
der as well as comparing urinary steroid metabolites uncorrected for 
 Control F0-2 F3-4 P-value
N (m/f) (males, %) 106 (41/65) 
(38.7)
39 (20/19) (51.3) 82 (39/43) (47.6) 0.29
Age, y 55.5 ± 11.1 45.6 ± 12.0* 61.8 ± 10.8*,** <0.0001
BMI, kg/m2 30.7 ± 5.8 38.5 ± 7.0* 33.7 ± 5.8*,** <0.0001
Proportion with 
type 2 diabetes, %
3.8 30.8* 63.4*,** <0.0001
HbA1c, mmol/mol 38.6 ± 10.4 40.8 ± 8.2 50.0 ± 13.5*,** <0.0001
Platelets, 10 y2/L n/a 242.5 ± 64.2 183.9 ± 67.0** <0.0001
ALT, IU/L 13.2 ± 8.7 63.4 ± 51.4* 49.9 ± 36.9* <0.0001
AST, IU/L n/a 34.4 ± 22.0 49.1 ± 31.8** 0.0006
Fib-4 score n/a 0.931 ± 0.7 2.61 ± 1.7** <0.0001
NAFLD fibrosis 
score
n/a 1.9 ± 1.2 3.8 ± 1.6** <0.0001
NAS score (0-8) n/a 4.0 ± 1.7 4.7 ± 1.3** 0.029
Proportion with 
NAS score ≥5, %
n/a 42.1 63.1 0.07
Note: Data expressed are mean ± standard deviation (unless otherwise stated). Where applicable, 
P-value stated in the final column is the summary ANOVA value when all three groups are 
compared (*P < 0.05 vs control; **P < 0.05 vs F0-2).
Abbreviations: BMI, body mass index; FIB-4, fibrosis-4 score; NAFLD, non-alcoholic fatty liver 
disease; NAS, NAFLD Activity Score.
TA B L E  1   Demographic details of 227 
subjects: 106 control and 121 individuals 
with biopsy-proven NAFLD stratified by 
fibrosis stage (F0-2 vs F3-4)
     |  5MOOLLA et AL.
urinary creatinine. There was no impact of gender on the GMLVQ 
model performance when analysis was undertaken directly comparing 
men vs women. In addition, when gender was added as a variable into 
the GMLVQ analysis, there was no alteration in the performance of the 
model to predict stage of disease (data not shown). AUC ROC analysis 
was similar using data from samples where uncorrected steroid me-
tabolite levels were expressed as μg steroid/1000 mL urine (Table S4). 
Furthermore, as NASH is an important feature in the disease spectrum 
of NAFLD, GMLVQ analysis was tested for its ability to predict NASH. 
GMLVQ analysis was unable to distinguishing between NASH (NAS 
>4) and non-NASH in those with established NAFLD (Figure S3).
3.4 | GMVLQ can be refined to include only 10 
urinary steroid metabolites without significant loss in 
diagnostic performance
A further GMLVQ analysis was performed with sequential removal 
of the least discriminatory steroid metabolites. GMLVQ analysis was 
then compared against the best-performing non-invasive serum 
markers (Fib-4 for F0-2 vs F3-4 and NAFLD fibrosis score for F0-3 vs 
F4). Refining the model from 32 metabolites to 10 (GMLVQ-10) did 
not result in any loss of diagnostic performance and GMLVQ analysis 
incorporating age and BMI using 10 steroid metabolites (GMLVQ-
10*) still out-performed FIB-4 (F0-2 vs F3-4) and NAFLD fibrosis 
score (F0-3 vs F4) (Figure 4A,B, Table 3). In addition, the analy-
sis of 10 most discriminatory steroids was still able to distinguish 
NAFLD cirrhosis from alcohol-related cirrhosis (GMLVQ-10*; AUC 
ROC = 0.82 [0.81-0.84, 95% confidence intervals]). The 10 most 
discriminatory steroids that had the most impact in distinguishing 
each of the clinical comparisons (F0-2 vs F3-4; F0-3 vs F4; Control 
vs F3-4; Control vs F4) are shown in Table 3.
4  | CONCLUSIONS
We have demonstrated for the first time that urinary steroid metab-
olome profiling in spot urine samples combined with machine learn-
ing-based analysis can accurately identify patients with NAFLD who 
have the most advanced stages of liver disease including cirrhosis 
F I G U R E  1   Total Glucocorticoid Metabolites, 
11β-hydroxysteroid dehydrogenase type 1 and 5α-reductase 
activities based on urinary multi-steroid profiling by GC-MS. 
Statistical analysis performed on log-transformed steroid values 
or ratios. Data shown: mean ± SD. Two and 4 data points not 
shown in (A) and (B), respectively, for graphical purposes. Both 
11β-hydroxysteroid dehydrogenase type 1 (A) and 5α-reductase 
(B) activities are increased in patients with NAFLD with advanced 
fibrosis, although not in those with mild disease when compared 
with controls. Total glucocorticoid metabolite production was not 
different across the spectrum of NAFLD or in comparison with 
controls (****P < 0.0001, *P < 0.05). NAFLD, non-alcoholic fatty 
liver disease
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(F3-F4). This novel urinary biomarker algorithm performed better 
than, or equivalently to the FIB-4 and NAFLD fibrosis scores, two 
commonly used noninvasive biomarkers in the evaluation of ad-
vanced liver fibrosis in patients with NAFLD.
The relationship between NAFLD fibrosis stage and clinical out-
come is now well-established.4 Furthermore, population-based studies 
have suggested a high prevalence of undiagnosed advanced NAFLD 
in the general population,16,17 and while screening is not currently 
advocated, identification of advanced fibrosis and cirrhosis would 
significantly alter patient management. If appropriate management 
strategies are to be implemented, investigative tools that do not carry 
the associated risks and limitations of liver biopsy are needed. There is 
therefore a pressing need for the development of accurate non-inva-
sive markers to determine stage of liver disease, fuelled, at least in part, 
by the poor performance of simple routine liver biochemistry.6
The number of potential tests that can be used to assess the risk 
of advanced fibrosis is large. Data from more than 20 different tests, 
algorithms or imaging platforms have been published7 and the large 
number of tests perhaps reflects the need for improved performance. 
The range of ROC AUC values is broad for many of these tests that are 
currently used in clinical practice, and although these can sometimes 
exceed 0.90, the majority of studies suggest values between 0.8 and 
0.9. The potential use of a urinary test is novel, completely non-inva-
sive, easily accessible and acceptable to patients and may easily be 
performed across both primary and secondary care opening the pos-
sibility of more widespread use in screening the general population. 
Urine sampling has a higher degree of patient acceptability than ve-
nepuncture; it requires no specialist sampling equipment or personnel 
and with further development, rapid high-throughput platforms may 
make urinary steroid GMLVQ analysis a cost-effective approach.
TA B L E  2   Comparison of GMLVQ analysis of urinary steroid metabolites vs serum assessments using Fib4 and NAFLD fibrosis scores 
(analysis of samples corrected for urinary creatinine)
Clinical comparison 
(NAFLD stage)
AUC ROC (95% confidence intervals)
NAFLD Fibrosis 
score FIB-4
GMLVQ (32 
steroids)
GMLVQ* (32 
steroids, age, 
BMI)
GMLVQ-10 
(top 10 steroid 
metabolites)
GMLVQ-10* (top 10 
steroid metabolites, 
age, BMI)
F0-F2 vs F3-F4 0.87 (0.86-0.88) 0.91 (0.89-0.92) 0.89 (0.87-0.90) 0.92 (0.91-0.94) 0.87 (0.85-0.88) 0.92 (0.91-0.94)
F0-F3 vs F4 0.87 (0.86-0.88) 0.84 (0.83-0.85) 0.87 (0.85-0.89) 0.92 (0.91-0.94) 0.85 (0.83-0.87) 0.90 (0.89-0.92)
Controls vs F0-F4  0.93 (0.92-0.94) 0.94 (0.92-0.95) 0.92 (0.91-0.93) 0.94 (0.93-0.96)
Controls vs F3-F4 0.99 (0.98-0.99) 0.98 (0.97-0.98) 0.99 (0.98-0.99) 0.98 (0.98-0.99)
Controls vs F4 1.00 (1.00-1.00) 1.00 (1.00-1.00) 1.00 (1.00-1.00) 1.00 (0.99-1.00)
Abbreviations: BMI, body mass index; FIB-4, fibrosis-4 score; GMLVQ, Generalised Matrix Learning Vector Quantisation; NAFLD, non-alcoholic fatty 
liver disease; ROC, receiver operating characteristics.
TA B L E  3   GMLVQ analysis identifies the 10 most discriminatory steroid metabolites for distinguishing clinically relevant stages of NAFLD
Discriminatory 
ranking
NAFLD stage comparison
F0-2 vs F3-4 F0-3 vs F4 Control vs F3-4 Control vs F4
1 Etiocholanolone Etiocholanolone 5α-tetrahydro-11-
dehydrocorticosterone
5α-tetrahydro-11-
dehydrocorticosterone
2 Dehydroepiandrosterone Tetrahydrocorticosterone 11-oxoetiocholanolone 11-oxoetiocholanolone
3 5α-tetrahydro-11-
dehydrocorticosterone
5α-tetrahydro-11-
dehydrocorticosterone
Etiocholanolone Etiocholanolone
4 Androstendione Tetrahydro-11 
deoxycorticosterone
Cortisone Cortisone
5 5α-tetrahydrocorticosterone Dehydroepiandrosterone Pregnenediol Tetrahydro-11 
deoxycorticosterone
6 Pregnenetriol Androsterone Pregnanetriol Pregnenediol
7 Tetrahydro-11 
deoxycorticosterone
Tetrahydrocortisone Tetrahydro-11 
deoxycorticosterone
Pregnanetriol
8 Tetrahydroaldosterone Tetrahydrocortisol 11β-hydroxyetiocholanolone Tetrahydrocorticosterone
9 Cortisone Pregnenetriol Pregnanediol Pregnanediol
10 11-oxoetiocholanolone 5α-tetrahydrocorticosterone 5α-tetrahydrocorticosterone 5α-tetrahydrocorticosterone
Abbreviations: GMLVQ, Generalised Matrix Learning Vector Quantisation; NAFLD, non-alcoholic fatty liver disease.
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Untargeted urinary metabolic profiling in small numbers of pa-
tients has been explored,18,19 but its diagnostic ability has not been 
interrogated in detail. Volatile organic compound generated via the 
gut microbiome and excreted in the urine have been examined in 
a very small exploratory pilot study with AUC ROC values of 0.73 
(0.45-0.92) to distinguish advanced disease.20
The liver is the main site of steroid hormone metabolism and 
we have hypothesised that the assessment of urinary steroid me-
tabolites may provide a functional assessment of liver that may 
differ according to NAFLD stage. Previous work has focussed 
on specific steroid pathways that appear to be dysregulated. For 
example, there is evidence for increased 11β-HSD1 activity (as 
observed in our cohort) in patients with NASH, and it has been 
postulated that the resultant increased cortisol generation may 
serve as auto-regulatory mechanism to limit local hepatic in-
flammation.9 In the same study (and contrasting with our data), 
5α-reductase activity (to clear metabolically cortisol through the 
generation of inactive tetrahydrocortisol) was decreased. The rea-
sons for this discrepancy are not clear, although the small number 
of participants and the lack of detailed histological staging (includ-
ing fibrosis stage) in the published studies need to be considered. 
An additional study has suggested liver fat content correlates with 
5β-reductase activity, catalysed by the enzyme AKRD1 that is al-
most exclusively expressed in the liver.10
There is clear biological plausibility in our approach. 
Manipulation of steroid metabolising enzyme activity can impact 
upon hepatic phenotype. Inhibition of 11β-HSD1 decreases hepatic 
steatosis (albeit with a modest effect size).21 Similarly, combined 
5α-reductase type 1 and 2 inhibition with dutasteride increased 
hepatic triglyceride accumulation as well as driving insulin resis-
tance.22,23 Furthermore, inflammatory stimuli have been shown 
to regulate the expression and activity of steroid metabolising en-
zymes.24 Although precise role in steroid hormone metabolism is 
yet to be determined, the recent identification of specific genetic 
variants in 17β-hydroxysteroid dehydrogenase type 13 (HSD17B13) 
adds further plausibility to our approach as this enzyme appears to 
protect from the development of chronic liver disease and hepa-
tocellular carcinoma with several studies demonstrating increased 
expression in NAFLD add further plausibility to our approach.25,26 
In addition, the ability of ethanol to regulate steroid hormone me-
tabolising enzymes has been described27 and this may underpin the 
ability of our analysis to distinguish NAFLD from alcohol-related 
cirrhosis.
Urinary steroid metabolome analysis using GMLVQ has been 
used to help differentiate benign from malignant adrenal tumours,28 
but its use in the context of NAFLD is entirely novel. Data from our 
study (AUC ROC >0.9) would suggest excellent potential for GMLVQ 
analysis of urinary steroids as a strategy for accurate identification 
F I G U R E  2   GMLVQ* analysis, including 
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advanced fibrosis (F0-2 vs F3-4)  
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FIB-4 (the best-performing serological  
test in this analysis) (B). The performance 
of GMLVQ* to identify patients with 
cirrhosis (F0-3 vs F4) is also very  
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demonstrating significant improvement 
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of those patients with advanced fibrosis. This may be relevant for 
identifying patients within the general population that have the 
most advanced liver disease who are at high risk of cardiovascular 
and hepatic co-morbidities and complications. Estimates suggest 
that prevalence of compensated cirrhosis is likely to rise in the gen-
eral population by more than 150% in some countries over the next 
10-15 years and therefore identification of these patients is of huge 
clinical significance.29
Our study is not without limitations. The data that we have 
presented are from a modest-sized cohort of patients, although 
biomarker exploration in the context of NAFLD has typically been 
undertaken in cohorts of this size.30 This was a retrospective study 
and the sizes and clinical characteristics did differ between groups; 
age, BMI and the prevalence of T2D were different. These are all 
important variables that need to be considered in determining the 
risk of advanced NAFLD. Age and BMI were included in the refined 
GMLVQ* model, however, the addition of variables relating to the 
presence or absence of T2D or the glycated haemoglobin numerical 
data did not improve the performance of the model (data not shown). 
The NAFLD cohort in this study had a higher prevalence of advanced 
fibrotic disease than would be expected in the general population, 
probably reflecting the fact that most patients were identified in 
secondary care. Furthermore, this may explain why some of the 
comparator non-invasive tests, such as the Fib-4, performed bet-
ter than has been observed in the published literature. Finally, the 
current methodology of GC-MS is time consuming and labour inten-
sive. However, it is entirely plausible that our analysis can be trans-
ferred to a high-throughput, more cost- and time-efficient liquid 
chromatography tandem mass spectrometry platform. With these 
limitations in mind, there is a clear need to validate the findings from 
this study in a larger independent cohort with detailed histological 
staging of disease and comprehensive clinical characterisation.
In conclusion, we have presented proof of principle for an en-
tirely novel approach to stage NAFLD. Adopting machine learning 
algorithms has allowed the generation of a meaningful biomarker 
that may have excellent future clinical utility in the assessment and 
staging of NAFLD, both in secondary care and also in the broader 
general population and may reduce the need for liver biopsy. A pro-
spective test validation study is now required prior to roll out of this 
novel, non-invasive approach into clinical practice.
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